Ronald Demuth

Torrey Pines Investment, Inc (Torrey Pines Investment) is a venture capital firm is founded in 2002 by Nikolay Savchuk.The firm is headquartered San Diego, California.

Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA.

Teal Ventures Management LLC (Teal Ventures) is a venture capital firm founded by Nikolay Savchuk, Ron Demuth, and Eddie Rodriguez in 2018. The firm Headquartered in San Diego, California.

Chromis Therapeutics, Inc. focuses on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. Its CHR101 has a potential to eradicate HBV and to efficiently cure chronically infected HBV patients, as compared to drugs currently on the market. The company was founded by Vadim Bichko and is headquartered in San Diego, CA.

Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market.

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.

Founded in 1997, Chicago-based Integrated Genomics™ specializes in research in microbial genomics, biochemistry, and gene expression. Its scientists has broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics™ has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions. Integrated Genomics™' products and services are based on ERGO™, its web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms. In 2010 Integrated Genomics, Inc.'s business operations were transitioned to a new corporation, IG Assets, Inc. With the original Integrated Genomics' team, IG Assets continues to provide the same ERGO-based microbial genomic products and service.